NAA Services for Anti-Mesothelin Antibody
As the first-in-class biotech developer and provider, scientists at Creative Biolabs focus on applying outstanding technologies to the discovery and development of natural autoantibodies (NAAs) services. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers. So far, we are able to provide a full range of anti-mesothelin marker services for disease diagnosis and therapeutic monitoring. Based on advanced technology and years of research, we are confident to provide high-quality, custom services that can greatly assist your NAA project.
Background of Anti-Mesothelin Antibody
Mesothelin (MSLN) is a cell-surface antigen implicated in tumor invasion discovered more than 20 years ago. It is normally present on the mesothelial cells in the pleura, peritoneum, and pericardium but is also highly expressed in many cancers. The MSLN gene encodes a precursor protein of 71 kDa that is processed to a 31 kDa shed protein called megakaryocyte potentiating factor (MPF) and a 40 kDa fragment that is glycosylphosphatidyl inositol (GPI)-anchored membrane protein. MSLN is highly expressed in epithelial malignant mesothelioma. High levels of soluble forms of MSLN have also been reported in patients' serum and in the stroma of tumors which represent a barrier for directing therapy to cellular targets. MSLN can act bidirectionally, either by directly activating intracellular pathways via its GPI domain. Cancer cells that possess an invasive phenotype express high amounts of membranous MSLN, rather than the cytoplasmic form. Due to this expression pattern, it makes mesothelin an attractive target for cancer therapy.
Fig.1 The function of mesothelin in pancreatic cancer. (Zhang, et al., 2016)
The Role of Anti-Mesothelin Antibody in Pancreatic Cancer
Pancreatic cancer (PC) is a devastating disease ranked as the 4th leading cause of cancer-related deaths in the United States. Pancreatic ductal adenocarcinoma (PDAC) is characterized by its highly immunosuppressive tumor microenvironment that limits T cell infiltration and induces T cell hypofunction. A study showed that mesothelin mRNA expression was present in 4 of 4 resected primary pancreatic cancers, and by immunohistochemistry, all 60 resected primary adenocarcinomas were mesothelin positive. The results showed that mesothelin was expressed in all 18 cases of pancreatic adenocarcinomas examined but absent in normal pancreas. Immunotherapy based on T cells modified with a chimeric antigen receptor (CAR) has been demonstrated to be a promising strategy for cancer treatment. Mesothelin is a promising target for CAR T cell therapy, as it is overexpressed in the majority of pancreatic cancers. MSLN-redirected chimeric antigen receptor T cell therapy has shown some efficacy in clinical trials. Therefore, it demonstrated that the anti-mesothelin CAR-T cells efficiently inhibit the growth of pancreatic cancer patient-derived xenograft and may be a potential novel treatment strategy for patients with PC.
What We Can Do About NAA?
NAAs have been found to play an innate-like role in protection against infectious agents and to exert homeostatic functions in a variety of experimental models. Aided by our well-established platforms and experienced scientists, we can provide comprehensive NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. A wide spectrum of NAA products is available for your choice. Our one-stop service can provide accurate, high through-put, specific data without extensive repeats.
Based on our proven and optimized platforms, Creative Biolabs offers high-quality custom services and products covering the entire NAA therapy development process to best suit your program and budget requirements, which can greatly assist your research. Please contact us for more information.
References:
- Zhang, L.; et al. Clinical significance of mesothelin in pancreatic cancer. Current Signal Transduction Therapy. 2016, 11(1): 9-12.
- Aurore, Morello. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discovery. 2016, 6(2): 133-137.
Related Services:
- NAA Services for Anti-Calcium and Integrin Binding 1 (CIB1) Protein
- NAA Services for Anti-Coactosin-Like Protein (CLP)
- NAA Services for Anti-Ezrin
- NAA Services for Anti-ENOA1, 2 Antibody